Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Assets: 2015-2025

Historic Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $372.7 million.

  • Cartesian Therapeutics' Assets fell 18.15% to $372.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.7 million, marking a year-over-year decrease of 18.15%. This contributed to the annual value of $435.0 million for FY2024, which is 42.61% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Assets stood at $372.7 million for Q3 2025, which was down 4.17% from $388.9 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Assets ranged from a high of $455.3 million in Q3 2024 and a low of $106.0 million during Q3 2023.
  • Over the past 3 years, Cartesian Therapeutics' median Assets value was $347.7 million (recorded in 2024), while the average stood at $312.8 million.
  • In the last 5 years, Cartesian Therapeutics' Assets plummeted by 40.52% in 2023 and then spiked by 329.41% in 2024.
  • Cartesian Therapeutics' Assets (Quarterly) stood at $159.9 million in 2021, then rose by 3.75% to $165.9 million in 2022, then surged by 83.89% to $305.1 million in 2023, then soared by 42.61% to $435.0 million in 2024, then dropped by 18.15% to $372.7 million in 2025.
  • Its Assets stands at $372.7 million for Q3 2025, versus $388.9 million for Q2 2025 and $409.1 million for Q1 2025.